Atai Life Sciences N.V. (ATAI)

$4.48 -0.80 (-15.15%)
Market Cap 1.25B
Revenue (ttm) 310,000.00
Net Income (ttm) -149.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -48,151.61%
Debt to Equity Ratio 0.00
Volume 10,284,041
Avg Vol 5,985,524
Day's Range N/A - N/A
Shares Out 233.78M
Stochastic %K 10%
Beta 1.59
Analysts Strong Sell
Price Target $12.12

Company Profile

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 282 0507
Address:
250 West 34th Street, New York, United States
Boxer81
Boxer81 Jun. 9 at 5:12 AM
$ATAI https://www.streetinsider.com/dr/news.php?id=26618808
0 · Reply
Hanaleimike
Hanaleimike Jun. 9 at 2:34 AM
$ATAI I read today ubs bought 25 mil q1 2026. And black tick bought more as well. Hmmm
0 · Reply
GeorgeJetson17
GeorgeJetson17 Jun. 9 at 2:30 AM
$ATAI I saw some posts about phase 3 initiation for BPL003, but can’t find any articles about it. Did they start enrolling patients? How did you find out?
1 · Reply
CuriousChimps
CuriousChimps Jun. 8 at 7:52 PM
$ATAI bit shocked at the price action and the strange phase 3 initiation, that could have pushed us higher. I’m wondering if there’s something cooking behind the scenes and they are In a black out period? Anyways added here
1 · Reply
InvestmentPropertease
InvestmentPropertease Jun. 8 at 7:17 PM
$ATAI selling my $DFTX and increasing my position here. Time to put profits to work and now’s the perfect time 💎
2 · Reply
OmFm
OmFm Jun. 8 at 7:05 PM
$ATAI classic HC reiterates a $25 price and this goes down.
0 · Reply
Geckofarts31
Geckofarts31 Jun. 8 at 6:50 PM
$ATAI picked up some calls today, averaged down on some already held… hopefully we can hold and recover the rest of the week. I feel like something is right around the corner with this company.
0 · Reply
Aitoldmeso
Aitoldmeso Jun. 8 at 6:06 PM
$ATAI been waiting for a pull back and consolidation period. Buying here on strong support.
0 · Reply
matrixtrade123
matrixtrade123 Jun. 8 at 5:56 PM
$ATAI dang Dogs $HELP is making ALL TIME LOWS left that Shit Show years ago when Doug was the Ringleader __ Top Gun Cannabis Stocks finally looking good !
0 · Reply
jmash
jmash Jun. 8 at 4:19 PM
$ATAI weird price action. Hitting 5 a couple weeks ago back below 4? Either a screaming buy or a hold
0 · Reply
Latest News on ATAI
AtaiBeckley Transcript: AGM 2026

Jun 4, 2026, 11:00 AM EDT - 4 days ago

AtaiBeckley Transcript: AGM 2026

AtaiBeckley Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 5 days ago

AtaiBeckley Transcript: Jefferies Global Healthcare Conference 2026

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

May 28, 2026, 9:00 AM EDT - 11 days ago

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

May 27, 2026, 6:00 AM EDT - 12 days ago

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

2026-05-14T18:50:44.000Z - 25 days ago

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

CMND CMPS DFTX ENVB GHRS MIRA NRXP

AtaiBeckley reports Q1 EPS (8c), consensus (11c)

2026-05-12T16:08:09.000Z - 27 days ago

AtaiBeckley reports Q1 EPS (8c), consensus (11c)

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

May 12, 2026, 8:00 AM EDT - 27 days ago

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

AtaiBeckley Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 27 days ago

AtaiBeckley Quarterly report: Q1 2026

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

May 9, 2026, 11:53 AM EDT - 4 weeks ago

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

ACTU VVOS

AtaiBeckley Transcript: Needham Virtual Psychedelics Forum

Apr 27, 2026, 11:00 AM EDT - 6 weeks ago

AtaiBeckley Transcript: Needham Virtual Psychedelics Forum

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

Apr 27, 2026, 4:05 AM EDT - 6 weeks ago

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

AtaiBeckley Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

AtaiBeckley Proxy statement: Proxy filing

AtaiBeckley Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

AtaiBeckley Proxy statement: Proxy filing

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

Apr 22, 2026, 6:00 AM EDT - 6 weeks ago

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

How Trump's psychedelics executive order could unlock stalled cannabis reform

Apr 20, 2026, 2:05 PM EDT - 7 weeks ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

CMPS DFTX HELP GHRS

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

Apr 20, 2026, 10:45 AM EDT - 7 weeks ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

CMPS DFTX GHRS

AtaiBeckley price target raised to $15 from $14 at Canaccord

2026-04-20T13:22:59.000Z - 7 weeks ago

AtaiBeckley price target raised to $15 from $14 at Canaccord

Psychedelic stocks rally with Trump's support

Apr 20, 2026, 8:26 AM EDT - 7 weeks ago

Psychedelic stocks rally with Trump's support

CMPS DFTX GHRS

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

Apr 20, 2026, 8:18 AM EDT - 7 weeks ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

CMPS GHRS DFTX

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

Apr 20, 2026, 6:43 AM EDT - 7 weeks ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

CMPS DFTX ENVB GHRS HELP

AtaiBeckley price target raised to $16 from $11 at Guggenheim

2026-04-17T12:28:41.000Z - 7 weeks ago

AtaiBeckley price target raised to $16 from $11 at Guggenheim

AtaiBeckley Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 12:45 PM EDT - 7 weeks ago

AtaiBeckley Transcript: 25th Annual Needham Virtual Healthcare Conference

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

Apr 14, 2026, 6:00 AM EDT - 7 weeks ago

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

Psychedelic: AtaiBeckley reports publication of BPL-003 study results

2026-04-09T15:00:20.000Z - 2 months ago

Psychedelic: AtaiBeckley reports publication of BPL-003 study results

NRXP PBM SILO

AtaiBeckley announces peer-reviewed Phase 2a results of BPL-003 study

2026-04-08T10:07:08.000Z - 2 months ago

AtaiBeckley announces peer-reviewed Phase 2a results of BPL-003 study

AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

Apr 8, 2026, 6:00 AM EDT - 2 months ago

AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

AtaiBeckley initiated with a Buy at Deutsche Bank

2026-03-27T08:55:15.000Z - 2 months ago

AtaiBeckley initiated with a Buy at Deutsche Bank

AtaiBeckley initiated with a Buy at Deutsche Bank

2026-03-26T23:25:13.000Z - 2 months ago

AtaiBeckley initiated with a Buy at Deutsche Bank

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

Mar 24, 2026, 6:00 AM EDT - 2 months ago

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

Psychedelic: AtaiBeckley reports publication of BPL-003 study results

2026-03-19T15:45:21.000Z - 2 months ago

Psychedelic: AtaiBeckley reports publication of BPL-003 study results

CMND ENVB IXHL JAGX NRXP SPRC

AtaiBeckley Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 8:00 AM EDT - 3 months ago

AtaiBeckley Transcript: Leerink Global Healthcare Conference 2026

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

Mar 10, 2026, 6:00 AM EDT - 3 months ago

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

AtaiBeckley Earnings release: Q4 2025

Mar 6, 2026, 12:30 PM EST - 3 months ago

AtaiBeckley Earnings release: Q4 2025

AtaiBeckley Annual report: Q4 2025

Mar 6, 2026, 12:30 PM EST - 3 months ago

AtaiBeckley Annual report: Q4 2025

AtaiBeckley Transcript: Investor Day 2026

Mar 6, 2026, 9:00 AM EST - 3 months ago

AtaiBeckley Transcript: Investor Day 2026

AtaiBeckley Slides: FY 2026

Mar 6, 2026, 9:00 AM EST - 3 months ago

AtaiBeckley Slides: FY 2026

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Mar 6, 2026, 7:00 AM EST - 3 months ago

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

AtaiBeckley Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 11:50 AM EST - 3 months ago

AtaiBeckley Transcript: TD Cowen 46th Annual Health Care Conference

AtaiBeckley Transcript: Study result

Feb 26, 2026, 8:00 AM EST - 3 months ago

AtaiBeckley Transcript: Study result

AtaiBeckley Press release: Study result

Feb 26, 2026, 8:00 AM EST - 3 months ago

AtaiBeckley Press release: Study result

AtaiBeckley Slides: Study result

Feb 26, 2026, 8:00 AM EST - 3 months ago

AtaiBeckley Slides: Study result

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

Feb 26, 2026, 7:00 AM EST - 3 months ago

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

Feb 20, 2026, 7:00 AM EST - 3 months ago

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

Jan 16, 2026, 7:00 AM EST - 5 months ago

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:00 AM EST - 5 months ago

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Dec 23, 2025, 7:00 AM EST - 5 months ago

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

AtaiBeckley Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 6:30 AM EST - 7 months ago

AtaiBeckley Transcript: Jefferies London Healthcare Conference 2025

Enhanced Fortifies Executive Leadership Team & Board of Directors

Nov 19, 2025, 7:32 PM EST - 7 months ago

Enhanced Fortifies Executive Leadership Team & Board of Directors

AtaiBeckley Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

AtaiBeckley Quarterly report: Q3 2025

AtaiBeckley Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

AtaiBeckley Earnings release: Q3 2025

AtaiBeckley Transcript: Study Result

Nov 10, 2025, 8:00 AM EST - 7 months ago

AtaiBeckley Transcript: Study Result

AtaiBeckley Press release: Study Result

Nov 10, 2025, 8:00 AM EST - 7 months ago

AtaiBeckley Press release: Study Result

AtaiBeckley Slides: Study Result

Nov 10, 2025, 8:00 AM EST - 7 months ago

AtaiBeckley Slides: Study Result

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Oct 20, 2025, 5:29 PM EDT - 8 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Oct 16, 2025, 10:31 PM EDT - 8 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences Announces Proposed Public Offering of Common Shares

Oct 16, 2025, 4:12 PM EDT - 8 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Oct 16, 2025, 4:10 PM EDT - 8 months ago

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

AtaiBeckley Proxy statement: Proxy Filing

Oct 16, 2025, 8:00 AM EDT - 8 months ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Proxy statement: Proxy Filing

Oct 10, 2025, 8:00 AM EDT - 8 months ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Proxy statement: Proxy Filing

Sep 29, 2025, 8:00 AM EDT - 9 months ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Proxy statement: Proxy Filing

Sep 24, 2025, 8:00 AM EDT - 9 months ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Proxy statement: Proxy Filing

Sep 23, 2025, 8:00 AM EDT - 9 months ago

AtaiBeckley Proxy statement: Proxy Filing

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Sep 23, 2025, 7:00 AM EDT - 9 months ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

AtaiBeckley Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 10:00 AM EDT - 9 months ago

AtaiBeckley Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

AtaiBeckley Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:30 AM EDT - 9 months ago

AtaiBeckley Transcript: H.C. Wainwright 27th Annual Global Investment Conference

AtaiBeckley Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 8:35 AM EDT - 9 months ago

AtaiBeckley Transcript: Cantor Global Healthcare Conference 2025

atai Life Sciences to Participate in September Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 10 months ago

atai Life Sciences to Participate in September Investor Conferences

AtaiBeckley Proxy statement: Proxy Filing

Aug 14, 2025, 8:00 AM EDT - 10 months ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

AtaiBeckley Earnings release: Q2 2025

AtaiBeckley Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

AtaiBeckley Quarterly report: Q2 2025

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:16 PM EDT - 11 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 25, 2025, 4:05 PM EDT - 11 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

AtaiBeckley Slides: Corporate Presentation

Jul 2, 2025, 8:30 AM EDT - 1 year ago

AtaiBeckley Slides: Corporate Presentation

AtaiBeckley Proxy statement: Proxy Filing

Jul 2, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Proxy statement: Proxy Filing

Jul 2, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Transcript: Study Update

Jul 1, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Transcript: Study Update

AtaiBeckley Press release: Study Update

Jul 1, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Press release: Study Update

AtaiBeckley Slides: Study Update

Jul 1, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Slides: Study Update

AtaiBeckley Proxy statement: Proxy Filing

Jul 1, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:05 AM EDT - 1 year ago

atai Life Sciences Announces $50 Million Private Placement Financing

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jul 1, 2025, 6:00 AM EDT - 1 year ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

AtaiBeckley Proxy statement: Proxy Filing

Jun 18, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 17, 2025, 7:00 AM EDT - 1 year ago

AtaiBeckley Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

AtaiBeckley Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 9:55 AM EDT - 1 year ago

AtaiBeckley Transcript: Jefferies Global Healthcare Conference 2025

AtaiBeckley Proxy statement: Proxy Filing

Jun 3, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Transcript: M&A Announcement

Jun 2, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Transcript: M&A Announcement

AtaiBeckley Press release: M&A Announcement

Jun 2, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Press release: M&A Announcement

AtaiBeckley Slides: M&A Announcement

Jun 2, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Slides: M&A Announcement

AtaiBeckley Proxy statement: Proxy Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Proxy statement: Proxy Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Proxy statement: Proxy Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Jun 2, 2025, 6:00 AM EDT - 1 year ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

atai Life Sciences to Participate in Upcoming Investor Conferences

May 29, 2025, 8:30 AM EDT - 1 year ago

atai Life Sciences to Participate in Upcoming Investor Conferences

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 20, 2025, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 14, 2025, 7:00 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

AtaiBeckley Quarterly report: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

AtaiBeckley Quarterly report: Q1 2025

AtaiBeckley Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

AtaiBeckley Earnings release: Q1 2025

AtaiBeckley Slides: Corporate Presentation

May 14, 2025, 7:00 AM EDT - 1 year ago

AtaiBeckley Slides: Corporate Presentation

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

May 13, 2025, 7:01 AM EDT - 1 year ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

AtaiBeckley Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Proxy statement: Proxy Filing

AtaiBeckley Annual report: Q4 2024

Mar 17, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Annual report: Q4 2024

AtaiBeckley Earnings release: Q4 2024

Mar 17, 2025, 8:00 AM EDT - 1 year ago

AtaiBeckley Earnings release: Q4 2024

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Mar 11, 2025, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

AtaiBeckley Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:50 AM EST - 1 year ago

AtaiBeckley Transcript: TD Cowen 45th Annual Healthcare Conference

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:10 PM EST - 1 year ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Jan 10, 2025, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

AtaiBeckley Quarterly report: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

AtaiBeckley Quarterly report: Q3 2024

AtaiBeckley Earnings release: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

AtaiBeckley Earnings release: Q3 2024

AtaiBeckley Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 16, 2024, 3:30 PM EDT - 1 year ago

AtaiBeckley Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Oct 2, 2024, 9:21 AM EDT - 1 year ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

AtaiBeckley Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 4:30 PM EDT - 1 year ago

AtaiBeckley Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

AtaiBeckley Slides: Corporate Presentation

Sep 10, 2024, 7:00 AM EDT - 1 year ago

AtaiBeckley Slides: Corporate Presentation

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

AtaiBeckley Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 14, 2024, 11:00 AM EDT - 1 year ago

AtaiBeckley Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

AtaiBeckley Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

AtaiBeckley Quarterly report: Q2 2024

AtaiBeckley Earnings release: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

AtaiBeckley Earnings release: Q2 2024

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS HELP DFTX

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

AtaiBeckley Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 27, 2024, 7:00 AM EDT - 2 years ago

AtaiBeckley Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 26, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

Jun 20, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

AtaiBeckley Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 10:00 AM EDT - 2 years ago

AtaiBeckley Transcript: Jefferies 2024 Global Healthcare Conference

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 31, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

AtaiBeckley Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

AtaiBeckley Quarterly report: Q1 2024

AtaiBeckley Earnings release: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

AtaiBeckley Earnings release: Q1 2024

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

May 15, 2024, 6:59 AM EDT - 2 years ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Boxer81
Boxer81 Jun. 9 at 5:12 AM
$ATAI https://www.streetinsider.com/dr/news.php?id=26618808
0 · Reply
Hanaleimike
Hanaleimike Jun. 9 at 2:34 AM
$ATAI I read today ubs bought 25 mil q1 2026. And black tick bought more as well. Hmmm
0 · Reply
GeorgeJetson17
GeorgeJetson17 Jun. 9 at 2:30 AM
$ATAI I saw some posts about phase 3 initiation for BPL003, but can’t find any articles about it. Did they start enrolling patients? How did you find out?
1 · Reply
CuriousChimps
CuriousChimps Jun. 8 at 7:52 PM
$ATAI bit shocked at the price action and the strange phase 3 initiation, that could have pushed us higher. I’m wondering if there’s something cooking behind the scenes and they are In a black out period? Anyways added here
1 · Reply
InvestmentPropertease
InvestmentPropertease Jun. 8 at 7:17 PM
$ATAI selling my $DFTX and increasing my position here. Time to put profits to work and now’s the perfect time 💎
2 · Reply
OmFm
OmFm Jun. 8 at 7:05 PM
$ATAI classic HC reiterates a $25 price and this goes down.
0 · Reply
Geckofarts31
Geckofarts31 Jun. 8 at 6:50 PM
$ATAI picked up some calls today, averaged down on some already held… hopefully we can hold and recover the rest of the week. I feel like something is right around the corner with this company.
0 · Reply
Aitoldmeso
Aitoldmeso Jun. 8 at 6:06 PM
$ATAI been waiting for a pull back and consolidation period. Buying here on strong support.
0 · Reply
matrixtrade123
matrixtrade123 Jun. 8 at 5:56 PM
$ATAI dang Dogs $HELP is making ALL TIME LOWS left that Shit Show years ago when Doug was the Ringleader __ Top Gun Cannabis Stocks finally looking good !
0 · Reply
jmash
jmash Jun. 8 at 4:19 PM
$ATAI weird price action. Hitting 5 a couple weeks ago back below 4? Either a screaming buy or a hold
0 · Reply
PreGigs
PreGigs Jun. 8 at 4:03 PM
$ATAI I didn't plan on buy anymore as I want to keep my 1.56 avg. But I guess I will - sheesh this ever hits the double digit I can easily take 10 year off work - maybe I'll live in Japan for a while
1 · Reply
Wallstreetiscriminal
Wallstreetiscriminal Jun. 8 at 4:01 PM
$ATAI Two questions. 1. Did they dump shares in to that price increase from the last couple of weeks? 2. Why do they need all our cash to do a trial that I’m reading will take two years, when the federal government has already been studying this stuff since the 1950’s? They know it works already, so are they just milking the cow a couple more years?
3 · Reply
stoxx0007
stoxx0007 Jun. 8 at 3:36 PM
$ATAI = ATAI Stands on its own merits, it doesn't need anyone pumping it. All the research speaks for itself. SCREAMING BUY!! 🤑🤑🤑
0 · Reply
matrixtrade123
matrixtrade123 Jun. 8 at 2:44 PM
$ATAI it is "imperative" to be included in the Russell 2000 come June 26 otherwise I see no catalyst until we get some data __ CA does not even mention ATAI anymore too busy with enhancements?
1 · Reply
Boxer81
Boxer81 Jun. 8 at 2:17 PM
$ATAI manipulated, not worry at all
0 · Reply
Hanaleimike
Hanaleimike Jun. 8 at 1:52 PM
$ATAI this was a dollar more last week. Now in phase 3 and it drops in silence. Where you at CA?
1 · Reply
Sailingsoon
Sailingsoon Jun. 8 at 1:50 PM
$ATAI solid Company clear course strategy in Place and Stage 3 will blow out Everything
0 · Reply
BobbyCucumber
BobbyCucumber Jun. 8 at 1:47 PM
$ATAI You guys need to ignore leBlewWho, he's just freaking out because he's not diversified In the sector, don't fall for his ridiculous statements, it's bloviated nonsense. I was equal weight in the top four companies, now DFTX and CMPS are worth 3-4x as much as ATAI and HELP. Great but sucks also, that's the way the cookie crumbles...
0 · Reply
Hanaleimike
Hanaleimike Jun. 8 at 1:42 PM
$ATAI maybe I need to learn how to short instead of riding these biopharm down.
0 · Reply
RSMK426
RSMK426 Jun. 8 at 1:35 PM
$ATAI this thing is done
0 · Reply
Hanaleimike
Hanaleimike Jun. 8 at 1:31 PM
$ATAI annnnnnd we are off.
0 · Reply
leLu83
leLu83 Jun. 8 at 1:01 PM
$ATAI the price goes up considerably after dosing. I suspect a multi national co collaboration takes time to structure. We are fully funded and well capitalized to see read outs and approval soon. We astutely ran 2 studies, one with 12 weeks end point. The data and rush tk approval will be swift. If youre suspect just read the efficacy data. Its the best. Numbers dont lie. Once these numbers are matched in p3 it becomes an instant blockbuster in market.
1 · Reply